Chronic Kidney Disease Is Common, Quiet, and Often Missed

HormoneSynergy® Longevity Medicine
Evidence-Based Preventive Longevity Medicine
Published September 18, 2026

Chronic kidney disease rarely gets the attention given to cholesterol, blood sugar, blood pressure or body weight, even though it is closely connected to all four. The kidneys filter waste from the blood, regulate fluid and electrolytes, participate in blood-pressure control and influence several other aspects of cardiovascular and metabolic physiology. When kidney function begins to decline, the effects can extend well beyond the kidneys themselves.

The difficulty is that early chronic kidney disease often causes no symptoms. According to the CDC’s 2026 estimates, approximately 37 million U.S. adults have CKD, representing about 14% of the adult population. About 87% of adults with CKD are estimated to be unaware that they have it. The prevalence rises sharply with age and is particularly high among people with diabetes and high blood pressure.

Kidney assessment has also become more nuanced than checking whether a serum creatinine result falls inside a laboratory reference range. Muscle mass, age, diet, medications, exercise and creatine supplementation can all affect creatinine. Urinary albumin can reveal kidney damage even when filtration appears relatively preserved. Cystatin C can sometimes clarify kidney function when the creatinine-based estimate does not fit the person in front of us.

This is increasingly being recognized outside nephrology. The 2026 American Heart Association, American College of Cardiology, American Diabetes Association and American Society of Nephrology guideline on cardiovascular-kidney-metabolic syndrome places kidney function directly alongside cardiovascular and metabolic risk. A separate American Heart Association scientific statement published September 17, 2026 also examines ways kidney disease may be overlooked in women and why reproductive and hormonal history can add useful clinical context.

CKD Is Common, but the Numbers Need Context

The CDC’s March 2026 report estimates that more than one in ten American adults has chronic kidney disease. CKD was estimated in 38% of adults with diabetes and 21% of adults with high blood pressure, while prevalence increased from approximately 6% among adults ages 18 to 44 to 34% among those 65 and older.

Those estimates help show the scale of the problem, although they also come with an important limitation. The CDC calculations are based on single measurements of serum creatinine and urinary albumin. Clinical CKD generally requires evidence that an abnormality has persisted for at least three months, so population estimates and an individual diagnosis are not the same thing.

One abnormal kidney result should be investigated rather than automatically labeled as chronic disease. At the same time, a normal-looking creatinine should not be allowed to end the discussion when the rest of the patient’s history suggests kidney risk.

Kidney Assessment Is More Than a Creatinine Result

Serum creatinine remains an important part of kidney evaluation because it is used to estimate glomerular filtration rate, or eGFR. The eGFR provides an approximation of how effectively the kidneys are filtering blood. It is useful for identifying reduced filtration, following change over time and helping classify the severity of established CKD.

Filtration is only part of kidney health. The urine albumin-to-creatinine ratio, usually abbreviated uACR, measures whether albumin is leaking into the urine. Healthy kidneys normally retain most albumin in the bloodstream. Persistent albuminuria can indicate kidney damage and is also associated with higher cardiovascular risk.

The 2026 cardiovascular-kidney-metabolic guideline specifically recommends using both eGFR and uACR to characterize CKD and guide risk assessment. This is particularly important because a person can have albuminuria while eGFR remains relatively well preserved, or reduced filtration without marked albuminuria.

Albuminuria also needs context. Strenuous exercise, fever, infection and several other temporary conditions can increase urinary albumin, which is one reason an unexpected result may need to be repeated rather than interpreted as permanent kidney damage.

Muscle Mass Changes What Creatinine Means

Creatinine is produced through normal muscle metabolism, so interpreting it without considering body composition can be misleading. An older adult who has lost substantial lean mass may produce relatively little creatinine. In that setting, serum creatinine can look reassuring even though kidney filtration has declined. A muscular person may produce more creatinine and have a lower calculated eGFR without having the degree of kidney impairment that the number initially suggests.

Recent meat intake, strenuous exercise, certain medications and creatine supplementation can also influence serum creatinine. None of these factors makes creatinine useless. They simply reinforce the need to interpret a laboratory value in the context of the person producing it.

This has become particularly relevant in longevity and metabolic medicine, where body composition may change considerably over time. Someone losing weight with a GLP-1-based therapy may lose fat, muscle or both. Someone beginning resistance training may gain lean mass. Older adults may experience progressive sarcopenia despite little change on the scale. These changes can affect the interpretation of creatinine-derived kidney estimates.

For more on why lean mass and visceral fat matter clinically, see the HormoneSynergy® Body Composition and Longevity Medicine guide.

When Cystatin C Can Help

Cystatin C is another blood marker that can be used to estimate kidney filtration. Compared with creatinine, it is less directly dependent on muscle mass, making it useful in selected patients whose body composition makes a creatinine-based eGFR less reliable.

KDIGO supports using an equation that combines creatinine and cystatin C when greater accuracy is needed and when the result is likely to affect clinical decision-making. This can be particularly helpful with unusual muscle mass, frailty, significant sarcopenia or an eGFR result that seems inconsistent with the rest of the clinical picture.

Cystatin C is not a perfect kidney marker and should not be treated as one. Inflammation, thyroid disease, corticosteroid exposure and other factors can influence it. The value of cystatin C is that it provides another view of filtration when creatinine alone leaves uncertainty.

Kidney, Cardiovascular and Metabolic Health Overlap

For years, kidney disease, cardiovascular disease and metabolic disease were often discussed as separate clinical problems. The biology does not cooperate with those boundaries particularly well.

High blood pressure can damage the kidneys, while declining kidney function can make blood-pressure management more difficult. Diabetes remains a major cause of CKD. Visceral adiposity and insulin resistance contribute to hypertension and metabolic dysfunction. Albuminuria identifies kidney damage while also carrying cardiovascular implications. Patients with CKD have substantially greater cardiovascular risk than people with otherwise similar health profiles and normal kidney function.

The first U.S. clinical guideline devoted specifically to cardiovascular-kidney-metabolic syndrome was published in 2026. Its central premise is clinically practical: cardiovascular disease, CKD, obesity, diabetes and related metabolic disorders frequently develop together and should be evaluated as an interconnected pattern rather than managed in isolation.

That approach fits with the way we already think about preventive care at HormoneSynergy®. Kidney function belongs in the same discussion as blood pressure, glucose regulation, insulin resistance, visceral fat, lipids, vascular disease and physical function. Our Preventive Cardiology and Cardiometabolic Health guide and Obesity, Metabolic Syndrome and Kidney Health article explore this overlap in more detail.

Kidney Health in Men and Women

The major CKD risks apply to both sexes. Hypertension, diabetes, cardiovascular disease, smoking, obesity, aging, family history, previous kidney injury and certain medications all deserve attention in men and women. Kidney testing itself is also built around the same core measurements.

There are, however, additional pieces of history that can matter.

The American Heart Association’s September 17, 2026 scientific statement, Women’s Kidney Health in Focus, describes several areas in which kidney risk in women has received insufficient attention. Pregnancy complications and hypertensive disorders of pregnancy can have implications for future cardiovascular and kidney health. Autoimmune diseases that can involve the kidneys are more common in women. PCOS and associated metabolic dysfunction can add another layer of risk, while early natural menopause and premenopausal oophorectomy have been associated with later kidney outcomes in observational research.

The statement also points out that women remain underrepresented in parts of the CKD therapeutic literature and that sex-specific differences in drug handling and treatment response need more study. This is a scientific statement rather than a new screening guideline, and some of the associations involving reproductive aging remain observational. The practical lesson is not that every woman requires a different kidney panel. It is that pregnancy and reproductive history can contain cardiovascular and renal information worth documenting.

Men have their own interpretive issues. Greater average muscle mass can raise creatinine, and resistance training or creatine supplementation can complicate interpretation further. A higher creatinine result in a muscular man should not automatically be dismissed as muscle-related, but neither should it automatically be taken as proof of kidney disease. The same principle applies in the opposite direction to an older adult with very little muscle: the laboratory value has to be reconciled with body composition, history and the trend over time.

Lifestyle Is Part of Kidney Treatment

The growth of effective kidney-protective medications has changed CKD care, but it has not reduced the importance of the factors that often contribute to kidney disease in the first place. Blood pressure, diabetes, body composition, smoking, nutrition and physical activity remain clinically relevant whether or not medication is required.

Blood pressure and metabolic health

Hypertension is one of the most important modifiable kidney risks and one of the most common consequences of declining kidney function. Home blood-pressure measurements can add useful information to office readings, particularly when blood pressure is variable or treatment is being adjusted.

Glucose regulation deserves the same attention. Diabetes remains a major driver of CKD, which means kidney prevention often begins before an individual has advanced kidney disease. Improving glycemic control, insulin sensitivity, blood pressure and body composition can reduce the metabolic environment that contributes to kidney and cardiovascular injury.

Visceral fat is especially relevant because it tends to travel with insulin resistance, hypertension, abnormal lipids, fatty liver disease and the broader CKM picture. For patients trying to lose weight, the aim should not simply be a lower number on the scale. Preserving muscle while reducing excess visceral and total fat usually provides a more useful metabolic target.

Exercise and physical function

Regular physical activity can improve blood pressure, insulin sensitivity, cardiovascular fitness and body composition. People with CKD do not automatically need to avoid exercise, although the appropriate amount and intensity should reflect kidney stage, cardiovascular status, anemia, frailty, medications and overall physical capacity.

Resistance training becomes particularly important with aging because CKD and sarcopenia can coexist. Maintaining muscle supports mobility, glucose disposal and physical independence, but exercise and protein recommendations need to be adjusted when kidney disease is established rather than borrowed wholesale from fitness culture.

Sodium and food quality

Sodium intake can influence blood pressure and fluid balance, particularly in people with hypertension or more advanced CKD. Most dietary sodium in the United States comes from restaurant meals, packaged foods, processed meats, sauces and other prepared foods rather than from salt added at the table.

A kidney-supportive diet does not need to begin as a complicated list of forbidden foods. For many patients, improving food quality, reducing heavily processed foods, controlling excess sodium and aligning carbohydrate intake with metabolic health are reasonable starting points. More advanced CKD may require individualized attention to potassium, phosphorus, protein and fluid intake, which is where dietitian or nephrology guidance becomes increasingly important.

Protein requires more nuance when CKD is present

Protein deserves particular attention because one of the dominant messages in healthy-aging medicine has been to increase protein intake in order to preserve muscle. That can be appropriate for many adults, but established CKD changes the calculation.

The current KDIGO guideline suggests maintaining protein intake at approximately 0.8 grams per kilogram of body weight per day in adults with CKD stages G3 through G5 and advises avoiding high protein intake above approximately 1.3 g/kg/day in people with CKD who are at risk of progression.

That recommendation is not intended to create malnutrition. KDIGO specifically recognizes the importance of sarcopenia, frailty, cachexia and inadequate energy intake. Dialysis changes protein requirements as well. An older adult losing muscle should not be treated exactly like a younger adult with stable body composition simply because both carry a CKD diagnosis.

This is a good example of why longevity nutrition has to remain individualized. Muscle matters, and kidney function matters. The clinical job is to protect both as well as possible rather than allowing either objective to become an absolute rule.

Smoking, medications and supplements

Smoking increases cardiovascular and kidney risk and remains an important intervention point. Medication review matters as well. Nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen can worsen kidney function in susceptible patients, particularly with frequent use, dehydration or certain combinations of blood-pressure and diuretic medications.

Supplements should be reviewed with the same seriousness. Kidney disease can alter the handling of minerals and other compounds, and a product being sold as natural does not guarantee that it is appropriate for someone with reduced filtration. Patients with established CKD should make sure the clinicians managing their care know about prescription medications, over-the-counter drugs, protein products, creatine, herbs and supplements.

Modern CKD Care Is More Than Observation

There was a time when patients with early kidney decline were often told little more than to control blood pressure, control diabetes and repeat the laboratory testing later. Those recommendations still matter, but there are now therapies that can materially reduce kidney and cardiovascular risk in appropriately selected patients.

The specific treatment depends on why CKD is present, the degree of albuminuria, eGFR, diabetes status, heart failure, blood pressure and overall cardiovascular risk. Depending on that picture, guideline-directed therapy may include renin-angiotensin system inhibitors, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists and GLP-1-based therapies.

The 2026 CKM guideline recommends both eGFR and uACR partly because these measurements do more than describe kidney function. They can help identify patients who may benefit from kidney-protective treatment. KDIGO also began a focused update of its 2024 CKD guideline in March 2026 because evidence surrounding SGLT2 inhibitors, GLP-1-based therapies and nonsteroidal mineralocorticoid receptor antagonists continues to develop.

For patients, the larger point is that early recognition increasingly has therapeutic value. Finding CKD before symptoms develop can create opportunities to address the factors driving it and, when appropriate, use treatments shown to reduce progression and cardiovascular events.

The Gut-Kidney Axis Is an Emerging Part of the Story

The intestinal microbiome has become another area of kidney research, although this field is at a much earlier stage than blood-pressure control, SGLT2 therapy or the other established parts of CKD management.

As kidney function declines, changes can occur in the intestinal environment and microbial ecosystem. At the same time, intestinal bacteria participate in the production of metabolites that normally depend partly on the kidneys for clearance. Two of the most studied are indoxyl sulfate and p-cresyl sulfate. These gut-derived uremic compounds can accumulate as filtration declines and are being investigated for their possible contributions to inflammation, vascular dysfunction and CKD progression.

This has led to growing interest in whether diet, fiber, prebiotics, probiotics or synbiotics can alter the production or absorption of these metabolites. The underlying biology is plausible, and several clinical trials have reported changes in individual biomarkers. What has not yet been established is whether manipulating the microbiome reliably slows CKD progression or improves the clinical outcomes that matter most to patients.

Our broader discussion of microbiome science is available in the HormoneSynergy® Gut Microbiome Health Guide.

Where Renadyl® Fits

Renadyl® has attracted attention because it was developed specifically for kidney health rather than being marketed as a general digestive probiotic. It contains three selected probiotic strains, Streptococcus thermophilus KB19, Lactobacillus acidophilus KB27 and Bifidobacterium longum KB31, along with the prebiotic fibers xylo-oligosaccharide and inulin.

The proposed mechanism is sometimes described as “enteric toxin removal.” In practical terms, the idea is that selected intestinal microbes may metabolize nitrogen-containing compounds within the gastrointestinal tract and modify the production or handling of some gut-derived uremic metabolites. That is an interesting hypothesis, but it should not be interpreted as a probiotic taking over the filtration work of the kidneys.

Renadyl is also not quite as new as recent attention might suggest. A randomized, double-blind, placebo-controlled crossover trial was published in 2014 in dialysis patients. Twenty-two participants completed the study, and the investigators did not find statistically significant improvements in the principal measures of uremic toxins or quality of life, although several inflammatory measurements showed nonsignificant trends.

A 2024 randomized study provides more recent data. Sixty adults with stage 3 or 4 CKD were assigned to Renadyl or another multi-strain probiotic, Lobun Forte, for six months. The Renadyl group improved from baseline in several measurements, including BUN, creatinine, indoxyl sulfate, p-cresyl sulfate, quality-of-life scores and calculated eGFR.

The limitation is the study design. It was open-label and used another active probiotic as the comparison rather than placebo or standard care alone. Both groups improved in several measures. That makes the study useful for generating interest and further research, but it does not establish that Renadyl by itself improves kidney function or slows CKD progression.

The broader probiotic literature reaches a similar conclusion. A 2024 meta-analysis of 21 studies found modest pooled improvements in BUN and C-reactive protein, while a Cochrane review found substantial variability in strains, doses, study populations and outcomes and judged much of the evidence uncertain. A 2026 review of clinical trials likewise concluded that microbiome-targeted interventions may improve some surrogate biomarkers, while effects on kidney function and long-term clinical outcomes remain inconclusive.

For HormoneSynergy®, that makes Renadyl an interesting adjunct rather than foundational CKD therapy. It has more kidney-specific clinical research behind it than an ordinary general-purpose probiotic, but the evidence is not strong enough to claim that it prevents CKD progression, prevents dialysis or replaces established medical treatment.

People with advanced CKD, a kidney transplant, significant immune compromise, dialysis or complex medical treatment should discuss probiotic use with the clinicians managing their kidney disease.

What a Practical Kidney Review Can Include

Kidney health is best understood as a pattern rather than a single result. In someone with meaningful risk factors, the discussion may include:

• Serum creatinine and how it has changed over time
• Creatinine-based eGFR
• Urine albumin-to-creatinine ratio
• Cystatin C when the creatinine-based estimate may be unreliable
• Blood pressure, including home measurements when appropriate
• Glucose and diabetes status
• Body composition and muscle mass
• Cardiovascular risk
• Medication and supplement exposure
• Smoking history
• Family history of kidney disease
• Previous kidney injury, kidney stones or structural urinary disease
• Relevant pregnancy and reproductive history in women

The direction of change is often as important as the individual result. A progressively declining eGFR, increasing albuminuria or laboratory findings that do not make sense in the context of the patient’s body composition deserve closer evaluation rather than automatic reassurance based on a single reference range.

Why Kidney Health Belongs in Longevity Medicine

There is no shortage of attention being paid to biological-age testing, novel peptides, elaborate supplement programs and emerging longevity technology. Meanwhile, chronic kidney disease remains common, frequently unrecognized and strongly associated with cardiovascular disease and premature mortality.

That is an important perspective check. Before pursuing increasingly exotic measurements, it is worth knowing whether the kidneys are filtering normally, whether albumin is appearing in the urine, whether blood pressure is controlled and whether diabetes or metabolic dysfunction is placing additional stress on the renal and cardiovascular systems.

None of this is particularly glamorous. It is simply useful medicine.

Kidney disease is one of the clearest examples of what prevention can look like when testing is connected to clinical action. Detect meaningful changes early, understand why they are occurring, address the factors that can be changed and use appropriate medical treatment when the evidence supports it.

For additional education across cardiovascular, metabolic, body-composition, gut and healthy-aging topics, visit the HormoneSynergy® Longevity Medicine Resource Library.

Questions Patients Often Ask

Can someone have kidney disease even if creatinine is normal?

Yes. Serum creatinine is influenced by muscle mass and other factors, and kidney damage can sometimes be present despite a creatinine result that does not appear concerning. eGFR, urinary albumin, clinical history and, in selected cases, cystatin C can provide additional information.

Why check urine albumin if an eGFR has already been calculated?

They measure different aspects of kidney health. eGFR estimates filtration, while uACR looks for abnormal leakage of albumin into the urine. Albuminuria can identify kidney damage and cardiovascular risk even when filtration remains relatively preserved.

Should everyone with CKD eat a low-protein diet?

No. Protein intake should reflect CKD stage, progression risk, age, nutritional status, muscle mass and whether a person is receiving dialysis. KDIGO suggests approximately 0.8 g/kg/day for many adults with CKD stages G3–G5 while emphasizing the need to avoid malnutrition and account for sarcopenia and other individual factors.

Does creatine damage the kidneys?

Creatine supplementation can raise serum creatinine because creatinine is a breakdown product related to creatine metabolism. That can complicate interpretation of creatinine-based eGFR. An increase in serum creatinine therefore needs clinical context rather than being assumed to represent either kidney injury or a harmless supplement effect.

Is Renadyl proven to treat chronic kidney disease?

Renadyl has been studied in people with CKD and dialysis, and the gut-kidney axis is an active area of clinical research. Current evidence is not strong enough to consider Renadyl a treatment that has been proven to slow CKD progression or replace established kidney-protective care. It is better viewed as a possible adjunct while additional research develops.

Related HormoneSynergy® Resources

• How Obesity and Metabolic Syndrome Stress the Kidneys
• Preventive Cardiology & Cardiometabolic Health
• Body Composition & Longevity Medicine
• The Gut Microbiome: Digestion, Immunity, Metabolism and the Gut-Brain Connection
• HormoneSynergy® Longevity Medicine Resource Library

Sources & Further Reading

• CDC: Chronic Kidney Disease in the United States, 2026
• American Heart Association: Women’s Kidney Health in Focus, 2026
• 2026 AHA/ACC/ADA/ASN Guideline for Cardiovascular-Kidney-Metabolic Syndrome
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
• KDIGO: Focused Update to the 2024 CKD Guideline, 2026
• Randomized Controlled Trial of Renadyl in Dialysis Patients
• 2024 Randomized Study Comparing Renadyl and Lobun Forte in Stage 3–4 CKD
• 2024 Systematic Review and Meta-analysis of Probiotics and Synbiotics in CKD
• Cochrane Review: Synbiotics, Prebiotics and Probiotics for People With CKD
• 2026 Review of Probiotics, Prebiotics and Synbiotics in Chronic Kidney Disease

Educational note: This article is intended for general education and does not provide a diagnosis or individualized treatment plan. Chronic kidney disease varies considerably by cause, stage, albuminuria, medications, cardiovascular risk, metabolic health, age and nutritional status. Testing, nutrition, supplements and treatment should be individualized with an appropriately qualified healthcare professional.